Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.60 |
| ▸ | POLA1 | P09884 | 1/20 | 0.58 |
| ▸ | POLG | P54098 | 1/20 | 0.58 |
| ▸ | HPRT1 | P00492 | 11/20 | 0.57 |
| ▸ | PNP | P00491 | 6/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17617678 | 1.00 | POLB (0.60) | POLBPOLA1POLGHPRT1PNP | |
| SCHEMBL17622514 | 0.95 | POLB (0.61) | POLBPOLA1POLGHPRT1PNP | |
| SCHEMBL17617324 | 0.91 | POLB (0.55) | POLBPOLA1POLGHPRT1PNP | |
| SCHEMBL10044384 | 0.91 | POLB (0.55) | POLBPOLA1POLGHPRT1PNP | |
| SCHEMBL16063251 | 0.90 | POLB (0.71) | POLBPOLA1POLGHPRT1PNP | |
| SCHEMBL16063241 | 0.90 | POLB (0.71) | POLBPOLA1POLGHPRT1PNP | |
| SCHEMBL16075000 | 0.90 | POLB (0.71) | POLBPOLA1POLGHPRT1PNP | |
| SCHEMBL19522032 | 0.88 | POLB (0.52) | POLBPOLA1POLGHPRT1PNP | |
| SCHEMBL10072433 | 0.86 | POLB (0.43) | POLBPOLA1POLGHPRT1 | |
| SCHEMBL16063284 | 0.85 | HPRT1 (0.61) | HPRT1PNP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8101745-B2 | Conjugate cidofovir, idoxuridine, vidarabine, trifluridine, acyclovir, famciclovir penciclovir, valacyclovir, ganciclovir, antiviral, antimicrobial, cancer drug of interest to glycerol ethers or glycerol phosphate ethers | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2012-01-24 | — | — | US | disclosed |
| US-20080221061-A1 | Lung-Targeted Drugs | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2008-09-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080221061-A1 | Lung-Targeted Drugs | DGKG, GK, PHOSPHO1 | POLB 4155/4885POLA1 4456/4885POLG 2538/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.